Prognostic Value of CEA and Ca 19.9/Tumor Markers in Gastric Cancer to Identify Patients with Poor Prognosis after Radical Surgery

Gastric cancer (GC) is still a vital malignant cancer across the world with unsatisfactory prognostic results. Matrilin-3 (MATN3) is a member of the extracellular matrix (ECM) protein family. The present research intends to explore the expression level of MATN3 in patients with GC and to explore the prognosis significance of MATN3. In this study, we observed that the MATN3 expression was remarkably upregulated in GC samples in contrast to noncancer samples. Clinical analyses unveiled that high MATN3 expression was related to age, tumor status, and clinical stages. Survival analyses unveiled that patients with high MATN3 expression displayed a poorer overall survival and progression-free survival than those with low MATN3 expression. The AUC of the relevant ROC curve for 1 year, 3 years, and 5 years of survival is 0.571, 0.596, and 0.720, separately. Multivariate assays revealed that MATN3 expression and stage were independent predictors of poor prognosis of GC patients. A meta-analysis unveiled that high MATN3 expression was tightly associated with better overall survival. Overall, our data indicated that MATN3 may have a diagnostic and prognostic value for patients with advanced gastric cancer and assist to improve clinical outcomes for GC patients.

Download Full-text

Prognostic Value of CEA and CA 19.9 in Gastric Cancer

World Journal of Oncology Research ◽

10.15379/2413-7308.2017.04.01 ◽

2017 ◽

Vol 4 ◽

pp. 1-6

Author(s):

F. López

Keyword(s):

Gastric Cancer ◽

Prognostic Value ◽

Ca 19.9

Download Full-text

Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50

Acta Cytologica ◽

10.1159/000445765 ◽

2016 ◽

Vol 60 (2) ◽

pp. 161-166 ◽

Cited By ~ 4

Author(s):

Edoardo Virgilio ◽

Enrico Giarnieri ◽

Monica Montagnini ◽

Rosaria D''Urso ◽

Antonella Proietti ◽

...

Keyword(s):

Gastric Cancer ◽

Tumor Markers ◽

Gastric Lavage ◽

Control Group ◽

Roc Curve Analysis ◽

Cutoff Value ◽

Ca 19.9 ◽

Ca 50 ◽

Gastric Cancer Patients

Objectives: To investigate gastric lavage (GL) cytopathology and immunometric analysis as novel clinicopathologic and prognostic parameters for gastric cancer (GC). Study Design: In 38 patients with gastric adenocarcinoma, we performed a cytopathologic analysis and an immunometric assay of GL using four tumor markers (CEA, CA 19.9, CA 72.4, and CA 50). The intragastric tumor marker levels were compared with a control group consisting of 41 non-GC patients to determine a statistically significant cutoff value. Results: GL cytopathology demonstrated the presence of cancer cells in 13 (34.2%) of the 38 GC patients: such a finding correlated to the parameters pT and pN with a statistically significant validity (p < 0.0267 and p < 0.0306, respectively). Measurement of intragastric CA 19.9 and CA 50 attained a statistically significant cutoff value (p < 0.002 and p < 0.0096, respectively), which was invalidated by the low sensitivity of the ROC curve analysis. Conclusions: In contrast to determination of its tumor markers, GL cytopathology correlated well with pT and pN staging parameters. Should this and other features be corroborated by future studies, the GL cytology test could be routinely used to detect aggressive types of GC even at early stages and result in important progress in the knowledge, staging, prediction, as well as management and follow-up of this inauspicious type of cancer.

Download Full-text

Clinical Significance and Prognostic Value of CA72-4 Compared with CEA and CA19-9 in Patients with Gastric Cancer

Disease Markers ◽

10.1155/2000/595492 ◽

2000 ◽

Vol 16 (3-4) ◽

pp. 105-110 ◽

Cited By ~ 79

Author(s):

M. Ychou ◽

J. Duffour ◽

A. Kramar ◽

S. Gourgou ◽

J. Grenier

Keyword(s):

Gastric Cancer ◽

Tumor Marker ◽

Poor Prognosis ◽

Prognostic Value ◽

Normal Values ◽

Univariate Analysis ◽

Neoplastic Disease ◽

Male Population ◽

Prognostic Information ◽

And Gender

Carcinoembryonic antigen (CEA) and CA 19-9 are both widely used in the follow up of patients with gastrointestinal cancer. More recently another tumor marker, named CA 72-4 has been identified and characterized using two different monoclonal antibodies B72.3 and CC49. Several reports evaluated CA 72-4 as a serum tumor marker for gastric cancer and compared its clinical utility with that of CEA or CA 19-9; few reports concerned its prognostic value. In the present study, CA 72-4 is evaluated and compared with CEA and CA 19-9 in various populations of patients with gastric cancer and benign disease; for 52 patients with gastric adenocarcinoma and 57 patients without neoplastic disease CEA, CA 19-9 and CA 72-4 were evaluated before treatment. Sensitivity of the tumor markers CA 72-4, CA 19-9 and CEA at the recommended cut-off level in all 52 patients were 58%, 50% the sensitivity increased to 75%. of these markers, for non metastatic patients, multivariate analyses indicated that none of the markers were significant, when adjusted for gender and age (which were indicators of poor prognosis); patients with abnormal values of CA72-4 tended to have shorter survival than patients with normal values (p< 0.07). In the metastatic population, only high values of CA19-9 (p< 0.02) and gender (women) (p< 0.03) were indicators of poor prognosis in univariate analysis; multivariate analysis revealed that both CA72-4 (p= 0.034) and CA19-9p= 0.009), adjusted for gender were independent prognostic factors. However, CA72-4 lost significance (p= 0.41) when adjusted for CA19-9 and gender, indicating that CA19-9 provides more prognostic information than CA72-4.When limited to the metastatic male population with normal values of CA 19-9 and CEA, CA 72-4 pretherapeutic positive levels were associated with a worse prognosis (p< 0.005).In conclusion, this study suggests that the addition of CA 72-4 to CEA and/or CA 19-9 could improve sensitivity in gastric cancer. The prognostic role of this marker is not yet clearly demonstrated but its usefulness in the monitoring of gastric cancer should be taken into account.

Download Full-text

Prognostic value of the number of metastatic lymph nodes in gastric cancer with radical surgery

Journal of Surgical Oncology ◽

10.1002/jso.2930530412 ◽

1993 ◽

Vol 53 (4) ◽

pp. 247-251 ◽

Cited By ~ 31

Author(s):

Hiroshi Isozaki ◽

Kunio Okajima ◽

Yasuo Kawashima ◽

Sinichi Yamada ◽

Eiji Nakata ◽

...

Keyword(s):

Gastric Cancer ◽

Lymph Nodes ◽

Prognostic Value ◽

Radical Surgery ◽

Metastatic Lymph Nodes ◽

Metastatic Lymph

Download Full-text

Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial

Gastric Cancer ◽

10.1007/s10120-021-01258-6 ◽

2021 ◽

Author(s):

Astrid E. Slagter ◽

Marieke A. Vollebergh ◽

Irene A. Caspers ◽

Johanna W. van Sandick ◽

Karolina Sikorska ◽

...

Keyword(s):

Gastric Cancer ◽

Tumor Markers ◽

Prognostic Value ◽

Cox Regression ◽

Multivariable Analysis ◽

Circulating Tumor Dna ◽

Curative Surgery ◽

Perioperative Therapy ◽

Resectable Gastric Cancer ◽

To Receive

Abstract Aim To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer. Methods We performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses. Likelihoods to receive potentially curative surgery were investigated for patients without elevated tumor markers versus one of the tumor markers elevated versus both tumor markers elevated. The association between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 patients with available ctDNA data. Results In multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11–1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42–2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters. Conclusion CEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position. Trial registration ClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.

Download Full-text